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Abstract Testing for treatment related biomarkers in clinical
care, like Ras mutation status in colorectal cancer (CRC), has
increased drastically over recent years. Reliable testing of the-
se markers is pivotal for optimal treatment of patients.
Participation in external quality assessment (EQA) programs
is an important element in quality management and often
obligatory to comply with regulations or for accreditation.
Formalin-fixed paraffin-embedded (FFPE) clinical specimens
would ideally form the basis for these assessments, as they
represent the most common starting material for molecular
testing. However, molecular heterogeneity of a lesion in a
FFPE tissue block could potentially affect test results of par-
ticipating laboratories, which might compromise reliability of
the quality assessment results. To assess the actual impact of
this potential problem, we determined the mutation status of
22 genes commonly mutated in colon cancer in four levels
covering 360 μm of 30 FFPE tissue blocks, by Next
Generation Sequencing. In each block, the genotype of these
genes was identical at all four levels, with only little variation
in mutation load. This result shows that the mutation status of
the selected 22 genes in CRC specimens is homogeneous
within a 360 μm segment of the tumor. These data justify
the use of serial sections, within a defined segment of a
CRC tissue block, for external quality assessment of mutation
analysis.
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Introduction
In recent years, testing of tumor-specific molecular bio-
markers to predict the putative response to targeted therapeu-
tics has increased rapidly. An example is the incorporation in
standard care of the mutation status of KRAS and NRAS,
which is decisive in starting epidermal growth factor receptor
(EGFR)-targeted therapy on metastatic colorectal cancer pa-
tients. The European Medicines Agency (EMA) declared that
the use of EGFR-targeted therapies should be restricted to
patients with a Ras wild-type tumor [1, 2]. Mutations in other
genes, such as BRAF and PIK3CA, are now tested in the con-
text of clinical trials and may enter clinical practice in the near
future.
Quality assessment is essential to validate the results of
these molecular tests, in order to achieve or sustain optimal
patient treatment [3]. Furthermore, quality assessment allows
comparison of inter-laboratory results, which is pivotal to de-
termine the effectiveness of a treatment regime instigated by
the result of a molecular test. To assure high quality of testing,
it is essential that each laboratory properly validates its
workflow of molecular tests, typically a sequence of tech-
niques [4–7] which for mutation screening consists of DNA
extraction, PCR amplification, sequencing, and detection. Test
results need to be validated, and participation in external qual-
ity assessment (EQA) programs is often obligatory to comply
with regulations or a requirement for accreditation as a test
provider [8, 9].
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Formalin-fixed paraffin-embedded (FFPE) tissue is the
most common startingmaterial for molecular testing, indepen-
dent of the exact workflow or test origin (laboratory devel-
oped test or commercially available). Therefore, they provide
the ideal basis for validation, EQA programs, and for compar-
ison of method performance. Reference samples need to yield
highly reproducible results over the participating laboratories.
This is easy to attain with homogeneous liquid samples from
which random samples can be drawn but potentially problem-
atic for serial tissue sections from an intrinsically heteroge-
neous tissue block. Reproducibility problems can arise due
to a variety of factors, including variation in the surface area
occupied by tumor tissue, proportion of neoplastic cells rela-
tive to stromal cells in tumor tissue and/or heterogeneity of
molecular abnormalities within a given block of tumor tissue.
Next generation sequencing (NGS) based techniques are
rapidly becoming the new standard to evaluate the mutation
status of a sample of tumor tissue. They provide highly sensi-
tive semi-quantitative information on all possible mutations in
a region of interest of the genome. To assess mutation status of
the most commonly mutated genes in colon cancer, a colon-
lung cancer panel was designed that allows reliable mutation
analysis (on only 10 ng of DNA) of the most frequently mu-
tated regions of the genes for receptor tyrosine kinases EGFR,
ERBB2, ERBB4, MET, ALK, FGFR1, FGFR2, FGFR3, and
DDR2, their pathway genes KRAS, NRAS, BRAF, PIK3CA,
and MAP2K1, as well as TP53, STK11, CTNNB1, SMAD4,
FBXW7, and NOTCH1, on only 10 ng of DNA [10].
We evaluated the reproducibility of genotyping for this
panel of tissue sections at different depths of CRC tissue
blocks, as this is important for the design of EQA schemes
evaluating gene testing for RAS and eventually other genes in
the panel, in view of the requirement that serial sections at




FFPE tissue samples from resected primary colorectal cancer
specimens, stage T3N0M0 or higher and with at least 40 % of
neoplastic cells, were obtained from 30 patients who had been
treated at the Radboud University Medical Center
(RadboudUMC) between 2007 and 2013. Six tumors were
microsatellite instable (MSI), 24 microsatellite stable (MSS),
and 8 were from patients treated with neoadjuvant chemother-
apy. The samples were anonymized for quality assessment
purposes, as a result of which they were not subjected to
research regulations of RadboudUMC, which require in-
formed consent and permission by the internal review board.
DNA extraction
FFPE blocks were cut to obtain 63 consecutive sections of
6 μm. H&E staining was performed on sections 1, 20, 40,
and 60. A pathologist assessed each stained section individu-
ally and selected the region for macrodissection and estimated
the percentage of neoplastic cells. Macrodissected tumor ma-
terial from two sections following each H&E stained section
was pooled for DNA extraction (Fig. 1). Tissue was digested
in 110 μl 5 % Chelex-100 resin (Bio-Rad laboratories,
Hercules, CA) and 2 mg/ml proteinase K in 10 mM
Tris/HCl (pH 8.5), 1 mM EDTA (pH 8.0), 0.01 % Tween-
20. Following overnight incubation at 56 °C, the enzyme
was heat inactivated at 95 °C for 10 min. After two rounds
of centrifugation (16,000 rpm for 1 min) the DNA in the
supernatant was quantified using the Qubit platform (Life
Technologies, Foster City, CA).
Sequencing
Bar-coded libraries were prepared from 10 ng DNA using the
Ion AmpliSeq Colon and Lung Cancer Panel version 1 (Life
Technologies), essentially as described by the manufacturer
except for amplification with 23 instead of 21 cycles. Clonal
amplification was subsequently performed by emulsion PCR
using the One Touch 2 system (Life Technologies). DNA
concentration of the resulting libraries was measured using
the Qubit platform (Life Technologies). Libraries were quan-
titatively pooled and run on the Ion Torrent Personal Genome
Machine (Life Technologies). Torrent Suite Software v.3.4.2
was used to pre-process raw data. Subsequently, sequence
alignment and variant calling were performed using SeqNext
Fig. 1 Schematic display of the use of the designated sections. All
sections had a thickness of 6 μm
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software v.4.1.2 (JSI medical systems GmbH, Kippenheim,
Germany). Each nucleotide was covered with a minimum of
at least 50 reads, and variants were included if theywere found
at an allelic frequency of at least 10 %.
Data analysis
Variants were filtered for known SNPs (MAF≥0.02), synon-
ymous mutations, and variants most likely to be false positive.
The latter were defined as variants present in most/all of
the 120 DNA samples. The remaining mutations were
assessed in the Catalogue of Somatic Mutations in
Cancer (COSMIC) database [11]. Variants not present in the
COSMIC database were subjected to Sanger sequencing to
confirm the somatic origin of the specific variant (in normal
and tumor tissue).
Differences between the percentages of mutated reads of
individual mutations at different levels of a tissue block were
evaluated by ANOVA, assuming repeated measurements.
Results
To assess reproducibility of genotyping within one FFPE co-
lorectal tumor tissue block, 63 sections of 6 μmwere cut from
30 different tumors. Sections 1 (level A), 20 (level B), 40
(level C), and 60 (level D) were histologically evaluated
(Fig. 1). Of each sample, a comparable region was
macrodissected at each level. The estimated percentage of
neoplastic cells was similar for the different levels within a
block with a maximum of 20% difference from level A (mean
3.56 %, st dev 5.67) (supplementary data).
Mutation analysis using the Ion AmpliSeq Colon and Lung
Cancer Panel version 1 (Life Technologies), was performed
on DNA isolated from the macrodissected region of sections 2
and 3 (level A), sections 21, and 22 (level B), sections 41, and
42 (level C) and sections 61 and 62 (level D). Because of poor
quality of the DNA from the initial isolation of tumor 18
sections 23 and 24, sections 43 and 44, and section 63 and
64 were used as levels B, C, and D, respectively. Variant
calling in KRAS (exon 2, 3, and 4), NRAS (exon 2 and 3),
BRAF (exon 15), and PIK3CA (exon 10 and 21) was
performed on nucleotide coverage of at least 160 reads. The
overall lowest mean coverage for these exons was 2396, with
a standard deviation of 1449 (Table 1).
The number of somatic mutations detected in the different
tumors varied from zero to five with a mean of 3.0 in micro-
satellite instable, 1.4 in microsatellite stable tumors of patients
not subjected to neoadjuvant therapy and 1.4 in microsatellite
stable tumors of patients subjected to neo-adjuvant therapy
(supplementary data). Mutations in KRAS, NRAS, BRAF, and
PIK3CA were detected in 9, 1, 6, and 5 tumors, respectively
(Table 2). The most frequently mutated gene was TP53, mu-
tated in 17 tumors. For all mutations the concordance detected
at levels A, B, C, and D was 100 %.
The percentage of variant reads was used to assess the
variation in mutation load at the different levels within
each tumor block. This varied between different mutations
within a given tumor (Fig. 2). However, for a specific
mutation the mutation load was stable at all four levels
(Fig. 3), as there were no significant differences in per-
centage of mutant reads between levels A, B, C, and D
(p=0.392). This indicates that NGS is highly reproducible
and that heterogeneity between sections at four different
levels of tissue blocks is limited.
Table 1 Coverage data of
individual fragments of KRAS,
NRAS, BRAF, and PIK3CA
KRAS BRAF NRAS PIK3CA
Exon 2 Exon 3 Exon 4 Exon 15 Exon 2 Exon 3 Exon 10 Exon 21
Min 186 278 256 175 162 160 233 194
Average 3009 4990 3304 2740 3572 3783 4597 3457
St. dev 1505 1963 1750 1449 1395 1396 1585 1376
Table 2 Mean percentage of mutated reads per gene
Average % mutated reads (st. dev)
Gene n Level A Level B Level C Level D
BRAF 6 39 (22) 38 (16) 38 (14) 39 (13)
DDR2 1 30 40 39 32
ERBB4 1 32 31 39 39
FBXW7 4 36 (7) 31 (4) 35 (7) 33 (3)
FGFR3 1 38 27 25 30
KRAS 9 37 (12) 36 (9) 39 (14) 35 (12)
MAP2K1 1 24 34 33 21
NRAS 1 34 39 39 43
PIK3CA 5 26 (4) 25 (6) 27 (4) 26 (6)
SMAD4 4 31 (9) 31 (12) 32 (8) 36 (7)
TP53 17 47 (17) 43 (15) 45 (16) 47 (16)
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Fig. 2 Percentage of mutated reads per mutation for each sample that
contains multiple mutations at different levels of the FFPE tissue block
(depth). Mutations are represented as color-coded (per gene) continuous
lines, except for sample 26 and 40 since in these samples more than one
mutation per gene was found
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Discussion
For each of 30 colorectal tumor blocks tested at four levels
separated by 120 μm (hence, a segment of 360 μm between
the upper and lower level), the genotype of 22 genes analyzed
by next generation sequencing was the same at all four levels.
Between different levels of a given tumor, little variation in the
percentage of mutant alleles was observed. This shows that
NGS-based genetic testing is reproducible and that different
levels in a single block of tumor tissue are homogeneous. The
results of these analyses justify the use of sections derived
from different levels of the same tumor block in current exter-
nal quality assessment schemes.
For this study, we selected samples with a relatively high
percentage of neoplastic cells to facilitate the detection of
mutations present in only a subset of neoplastic cells. The
mutation load of different mutations in a given tumor differed
by a factor two at most, which might reflect subtle copy num-
ber changes or copy number neutral loss of heterozygosity
events. In four samples (22, 24, 31, and 39), the percentage
of mutant alleles was less than 30 % of the percentage of
neoplastic cells, which is clearly lower than would be expect-
ed if one allele of a given diploid gene would be mutated in all
neoplastic cells. This might be due to overestimation of the
percentage of neoplastic cells by the pathologist, copy number
gains of wild-type alleles, or the presence of these mutations in
only a subset of the neoplastic cells. However, as in two (sam-
ple 22 and 39) of the three tumors this applies to mutations in
multiple genes residing on different chromosomes, overesti-
mation of the percentage of neoplastic cells is the most likely
explanation. Therefore, our results do not strongly indicate the
existence of tumor heterogeneity for the tested genes in this
setting.
In our study, we concentrated on only 30 tumors that were
judged eligible for use in quality assessment schemes. This
implied morphological homogeneity and avoidance of precan-
cerous regions that might harbor fewer mutations. Differences
in mutation load between morphologically different regions
within one slide were not examined. Moreover, we studied
regions that were at most 360 μm apart, which is far less than
the diameter of most tumors. Therefore, our data cannot be
used to argue in favor of homogeneity of mutation status
throughout an entire primary tumor.
In our next generation sequencing panel, we tested for mu-
tations in genes frequently mutated in colorectal cancer. The
panel allows the detection of mutations that are currently con-
sidered as actionable (NRAS, KRAS) or putatively actionable
(BRAF, PIK3CA) in colorectal cancer. The current design of
EQA schemes, which distribute sections from different levels
of a tissue block and aim at a sensitivity of 10 % mutant
alleles, seems therefore also appropriate for these putatively
actionable mutations. For reliable detection of mutant alleles
present at a lower percentage, other more sensitive approaches
would be necessary. However, the clinical relevance of muta-
tions in a low percentage of neoplastic cells is as yet not clear
and therefore is not an aim for current EQA schemes.
In conclusion, our data show that the percentage of mutant
alleles, of a panel of 22 genes including those that are fre-
quently mutated in colorectal cancer, is similar within a de-
fined depth of a block of colorectal cancer tissue. This justifies
the use of serial sections to assess the quality of mutation
analyses in different laboratories, as has become customary
in EQA schemes.
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